Patients with ICM who received MSCs via transendocardial stem cell injection ( TESI ) as part of the TAC-HFT ( Transendocardial Autologous Cells in Ischemic Heart Failure ) ( n = 19 ) and POSEIDON ( Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis ) ( n = 30 ) clinical trials were divided into 2 age groups : younger than 60 and 60 years of age and older .